Interaction of ceruloplasmin and 5-lipoxygenase

被引:0
|
作者
A. V. Sokolov
E. A. Golenkina
V. A. Kostevich
V. B. Vasilyev
G. F. Sud’ina
机构
[1] Research Institute of Experimental Medicine,Belozersky Institute of Physico
[2] Lomonosov Moscow State University,Chemical Biology
来源
Biochemistry (Moscow) | 2010年 / 75卷
关键词
protein-protein interaction; inflammation; leukotrienes; 5-lipoxygenase; ceruloplasmin;
D O I
暂无
中图分类号
学科分类号
摘要
The interaction between ceruloplasmin (CP), the multicopper oxidase of human plasma, and 5-lipoxygenase (5-LO), the key enzyme of leukotriene synthesis, is shown for the first time. By Western-blotting and mass spectrometry of tryptic fragments, it is shown that 5-LO from protein extract of human leukocytes binds with immobilized CP. Dose-dependent influence of intact CP on leukotrienes synthesis is found: CP reduced leukotrienes synthesis in leukocytes in a dose above 50 μg/ml (normal CP concentration in plasma is about 300–400 μg/ml). Proteolyzed CP and apo-form of CP is unable to inhibit activity of 5-LO. CP increased activity of 5-LO at low doses (5–10 μg/ml). On the whole, the influence of CP on phagocytosis index of leukocytes coordinates with influence on activity of 5-LO: the index increased in the range of 2–10 μg/ml CP and decreased at doses of CP above 40 μg/ml. The dual role of CP in regulation of cellular response of leukocytes is discussed.
引用
收藏
页码:1464 / 1469
页数:5
相关论文
共 50 条
  • [31] 5-Lipoxygenase Pathway in Experimental Abdominal Aortic Aneurysms
    Bhamidipati, Castigliano M.
    Whatling, Carl A.
    Mehta, Gaurav S.
    Meher, Akshaya K.
    Hajzus, Vanessa A.
    Su, Gang
    Salmon, Morgan
    Upchurch, Gilbert R., Jr.
    Owens, Gary K.
    Ailawadi, Gorav
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2014, 34 (12) : 2669 - 2678
  • [32] Pharmacotherapy of diseases mediated by 5-lipoxygenase pathway eicosanoids
    Rubin, Paul
    Mollison, Karl W.
    PROSTAGLANDINS & OTHER LIPID MEDIATORS, 2007, 83 (03) : 188 - 197
  • [33] 5-Lipoxygenase inhibitors: a review of recent developments and patents
    Pergola, Carlo
    Werz, Oliver
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2010, 20 (03) : 355 - 375
  • [34] 5-lipoxygenase, leukotrienes biosynthesis and potential antileukotrienic agents
    Jampilek, J
    Dolezal, M
    Opletalova, V
    Hartl, J
    CURRENT MEDICINAL CHEMISTRY, 2006, 13 (02) : 117 - 129
  • [35] On the interference of boswellic acids with 5-lipoxygenase: Mechanistic studies in vitro and pharmacological relevance
    Siemoneit, Ulf
    Pergola, Carlo
    Jazzar, Bianca
    Northoff, Hinnak
    Skarke, Carsten
    Jauch, Johann
    Werz, Oliver
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2009, 606 (1-3) : 246 - 254
  • [36] The 5-lipoxygenase pathway regulates vasculogenesis in differentiating mouse embryonic stem cells
    Finkensieper, Andreas
    Kieser, Sophia
    Bekhite, Mohamed M.
    Richter, Madeleine
    Mueller, Joerg P.
    Graebner, Rolf
    Figulla, Hans-Reiner
    Sauer, Heinrich
    Wartenberg, Maria
    CARDIOVASCULAR RESEARCH, 2010, 86 (01) : 37 - 44
  • [37] Flavonoids of cocoa inhibit recombinant human 5-lipoxygenase
    Schewe, T
    Kühn, H
    Sies, H
    JOURNAL OF NUTRITION, 2002, 132 (07) : 1825 - 1829
  • [38] The 5-lipoxygenase pathway in arterial wall biology and atherosclerosis
    Lötzer, K
    Funk, CD
    Habenicht, AJR
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 2005, 1736 (01): : 30 - 37
  • [39] Role of 5-lipoxygenase pathway in the pathophysiology of the aortic stenosis
    Akdemir, Ramazan
    Vatan, M. Bulent
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2011, 9 (07) : 853 - 855
  • [40] Regulating leukotriene synthesis: The role of nuclear 5-lipoxygenase
    Brock, TG
    JOURNAL OF CELLULAR BIOCHEMISTRY, 2005, 96 (06) : 1203 - 1211